Treatment News : NRTI Resistance May Blunt PI-to-Isentress Switch Effectiveness

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » June 2010

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

June 14, 2010

NRTI Resistance May Blunt PI-to-Isentress Switch Effectiveness

HIV-positive individuals with a history of nucleoside reverse transcriptase inhibitor (NRTI) resistance may be more likely to experience viral load rebounds upon switching to Isentress (raltegravir) from a protease inhibitor (PI), according to new data reported at the International HIV and Hepatitis Drug Resistance Workshop earlier this month in Dubrovnik, Croatia.

The study results, summarized by the National AIDS Treatment Advocacy Project (NATAP), may clarify data from the SWITCHMRK trials, in which people replacing Kaletra (lopinavir/ritonavir) with Isentress had a higher 24-week failure rate than people who continued Kaletra.

Archived NRTI mutations, NATAP explains, would put Merck’s integrase inhibitor Isentress at a disadvantage in the study because it has a lower barrier to resistance than Kaletra and because everyone who entered the trials had controlled HIV with PIs plus NRTIs.

In the study reported in Dubrovnik, Vincent Soriano, MD, and his colleagues at Madrid’s Carlos III Hospital randomized more than 200 patients, all of whom had an undetectable viral load for at least 24 weeks, to receive either once- or twice-daily Isentress.

According to NATAP’s report, 13 people (6 percent) experienced virologic failure within 24 weeks of switching from the PI to Isentress, including 12 in the once-daily Isentress group and one in the twice-daily group (this difference, however, was not statistically significant).

Twelve of 13 people with virologic failure had prior NRTI resistance—and only one person with virologic failure had no record of NRTI resistance—a difference that was statistically significant, meaning too great to have occurred by chance.

In an analysis conducted by the researcher, prior NRTI resistance raised the risk of Isentress failure more than 28 times.

The new study is not definitive, NATAP warns, because there was no control group in the study involving patients who continued their PI, similar to the SWITCHMRK design.

Search: Isentress, raltegravir, lopinavir, ritonavir, Kaletra, switch, SWITCHMRK, protease inhibitor, integrase inhibitor, nucleoside, NRTI, resistance


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    aqua_31206
    Macon
    Georgia


    romanticseattle
    Tacoma
    Washington


    usuallyhappy
    Palm Springs
    California


    RayOctober
    Richmond
    Virginia
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.